316 related articles for article (PubMed ID: 25065883)
1. Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension.
Ahad A; Al-Mohizea AM; Al-Jenoobi FI; Aqil M
Drug Deliv; 2016; 23(2):579-90. PubMed ID: 25065883
[TBL] [Abstract][Full Text] [Related]
2. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and lactation: an update.
Shannon ME; Malecha SE; Cha AJ
J Hum Lact; 2000 May; 16(2):152-5. PubMed ID: 11153347
[TBL] [Abstract][Full Text] [Related]
4. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
Ferrario CM
Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
[TBL] [Abstract][Full Text] [Related]
5. ARBs and ACEis together in the treatment of hypertension and its complications? current practical recommendations.
Ruilope LM; Segura J
Expert Opin Pharmacother; 2010 Nov; 11(16):2619-23. PubMed ID: 20977398
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
7. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
Verdecchia P; Gentile G; Angeli F; Reboldi G
Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation.
Zheng B; Kang J; Tian Y; Tang R; Long D; Yu R; He H; Zhang M; Shi L; Tao H; Liu X; Dong J; Ma C
Acta Cardiol; 2009 Jun; 64(3):335-40. PubMed ID: 19593943
[TBL] [Abstract][Full Text] [Related]
9. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.
Neutel JM
Curr Med Res Opin; 2010 Jan; 26(1):213-22. PubMed ID: 19921961
[TBL] [Abstract][Full Text] [Related]
10. The risk of hypertension after preoperative discontinuation of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists in ambulatory and same-day admission patients.
Twersky RS; Goel V; Narayan P; Weedon J
Anesth Analg; 2014 May; 118(5):938-44. PubMed ID: 24681657
[TBL] [Abstract][Full Text] [Related]
11. Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.
Wrona W; Budka K; Filipiak KJ; Niewada M; Wojtyniak B; Zdrojewski T
Kardiol Pol; 2016; 74(9):1016-24. PubMed ID: 27112942
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials.
Shahin Y; Khan JA; Samuel N; Chetter I
Atherosclerosis; 2011 May; 216(1):7-16. PubMed ID: 21411098
[TBL] [Abstract][Full Text] [Related]
13. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
14. Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
Swamy KM; Lin MJ; Sun CM
Mini Rev Med Chem; 2003 Sep; 3(6):621-31. PubMed ID: 12871164
[TBL] [Abstract][Full Text] [Related]
15. Drug Treatment of Hypertension: Focus on Vascular Health.
Cameron AC; Lang NN; Touyz RM
Drugs; 2016 Oct; 76(16):1529-1550. PubMed ID: 27667708
[TBL] [Abstract][Full Text] [Related]
16. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study.
Kristensen KE; Torp-Pedersen C; Gislason GH; Egfjord M; Rasmussen HB; Hansen PR
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):733-40. PubMed ID: 25633315
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II subtype 1 receptor blockers and renal function.
Toto R
Arch Intern Med; 2001 Jun; 161(12):1492-9. PubMed ID: 11427096
[TBL] [Abstract][Full Text] [Related]
19. Transdermal Delivery of AT1 Receptor Antagonists Reduce Blood Pressure and Reveal a Vasodilatory Effect on Kidney Blood Vessels.
Michalatou M; Androutsou ME; Antonopoulos M; Vlahakos DV; Agelis G; Zulli A; Qaradakhi T; Mikkelsen K; Apostolopoulos V; Matsoukas J
Curr Mol Pharmacol; 2018; 11(3):226-236. PubMed ID: 29676239
[TBL] [Abstract][Full Text] [Related]
20. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Lyle PA; Tershakovec AM; Devereux RB; Oparil S; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Wedel H
Expert Opin Emerg Drugs; 2005 Nov; 10(4):729-45. PubMed ID: 16262560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
